Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;37(1):95-105.
doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Axel S Merseburger  1 , Andrea B Apolo  2 , Simon Chowdhury  3 , Noah M Hahn  4 , Matthew D Galsky  5 , Matthew I Milowsky  6 , Daniel Petrylak  7 , Tom Powles  8 , David I Quinn  9 , Jonathan E Rosenberg  10 , Arlene Siefker-Radtke  11 , Guru Sonpavde  12 , Cora N Sternberg  13
Affiliations
Review

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Axel S Merseburger et al. World J Urol. 2019 Jan.

Abstract

The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

Keywords: Bladder cancer; Checkpoint inhibitors; Chemotherapy immunotherapy; Urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Axel S. Merseburger: Clinical trials: Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Roche, BMS, Merck. Speaker office: Amgen, Astellas, Bayer, Ferring, Hexal, Ipsen, Janssen, Novartis, Roche, Sanofi, TEVA. Consulting: GBA, TEVA, UEG, Janssen, BMS, Novartis, Merck, Roche, Takeda. Andrea B. Apolo: No disclosures. Simon Chowdhury: No disclosures. Noah M. Hahn: Consulting—Bristol Myers Squibb, AstraZeneca, Merck, Genentech, Pieris, Seattle Genetics, Ferring, TARIS, Rexahn, Incyte, Inovio. Research to Institution—Bristol Myers Squibb, AstraZeneca, Merck, Genentech, Pieris, Seattle Genetics, Inovio, Acerta. Honoraria—Bladder Cancer Academy. Matthew D. Galsky: Research funding: Merck, Genentech, BMS, Astra-Zeneca. Advisory Board: Merck, Genentech, BMS, Astra-Zeneca. Matthew I. Milowsky: No disclosures. Daniel Petrylak: No disclosures. Tom Powles: No disclosures. David I. Quinn: No disclosures. Jonathan E. Rosenberg: Stock and Other Ownership Interests: Merck, Illumina. Honoraria: UpToDate, Bristol-Myers Squibb, Astra-Zeneca, Medscape, Vindico, Peerview, Chugai Pharma. Consulting or Advisory Role: Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD SErono, Seattle Genetics, Bayer, Inovio Pharmaceuticals, BioClin Therapeutics, QED Therapeutics. Research Funding to Institution from Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genentech/Roche, Incyte. Patents, Royalties, Other Intellectual Property to Institution: Predictor of platinum sensitivity. Travel, Accommodations, Expenses: Genentech/Roche, Bristol-Myers Squibb. Arlene Siefker-Radtke: Scientific advisor: Merck, Eli Lilly, EMD Serono, Janssen, Bioclin. Guru Sonpavde: Consultant for Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, EMD Serono, Astellas; Research support to institution from Sanofi, Bayer, Boehringer-Ingelheim, Merck, BMS, Pfizer; Author for Uptodate; Speaker fees from Clinical Care Options, Physicians Education Resource (PER), Research to Practice (RTP), Onclive. Cora N. Sternberg: Consultant for BMS, Merck, Clovis. Sanofi, Bayer, Eli Lilly, Pfizer, Author for Uptodate, Speaker fees, Physicians Education Resource (PER).

References

    1. Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458 - PubMed
    1. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073 - PubMed
    1. von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077 - PubMed
    1. Sternberg CN, de Mulder PH, Schornagel JH et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor vs. classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646 - PubMed
    1. McConkey DCW, Shen Y, Lee I, Porten S, Matin S, Kamat A, Corn P, Millikan R, Dinney C, Czerniak B, Siefker-Radtke A (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Eurol 69:855–862 - PMC - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources